news
FDA approves Technivie for GT4 chronic HCV
27 July 2015 | By Victoria White
The US FDA has approved AbbVie’s Technivie in combination with ribavirin for the treatment of adults with genotype 4 chronic hepatitis C virus infection...
List view / Grid view
AbbVie
news
FDA orphan drug designation for C2N-8E12 for the treatment of progressive supranuclear palsy
20 July 2015 | By Victoria White
The US FDA has granted C2N-8E12 (ABBV-8E12) an orphan drug designation for the treatment of progressive supranuclear palsy (PSP)...
news
AbbVie to expand its medical device manufacturing facility in Ballytivnan
2 July 2015 | By Victoria White
AbbVie is to further expand its medical device manufacturing facility in Ballytivnan, Sligo, Ireland, and create 50 new highly-skilled jobs...
news
AbbVie announces new positive Phase 3b results in genotype 1b chronic HCV patients with compensated liver cirrhosis
24 June 2015 | By Victoria White
TURQUOISE-III study results demonstrate 100% sustained virologic response in genotype 1b chronic HCV patients with compensated liver cirrhosis...
news
AbbVie presents Phase 3 data demonstrating efficacy and safety of HUMIRA in children and adolescents with severe chronic plaque psoriasis
10 June 2015 | By Victoria White
Results from a pivotal Phase 3 study of HUMIRA demonstrate significant and clinically meaningful efficacy in children and adolescents with plaque psoriasis...
news
AbbVie presents Phase 2 results from study of veliparib in patients with NSCLC who are current smokers
3 June 2015 | By Victoria White
AbbVie has announced findings from a Phase 2 study of a veliparib regimen in patients with non-small cell lung cancer (NSCLC) who are current smokers...
news
Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression
3 June 2015 | By Victoria White
Results from an interim analysis of the Phase III ELOQUENT-2 trial of elotuzumab in combination with lenalidomide and dexamethasone have been announced...
news
AbbVie completes acquisition of Pharmacyclics
26 May 2015 | By Victoria White
AbbVie has completed the acquisition of Pharmacyclics, enhancing AbbVie's scientific and commercial presence in the haematological oncology market...
news
Abbvie receives Orphan Drug Designation for Humira for the investigational treatment of hidradenitis suppurativa
The US Food and Drug Administration (FDA) has granted Abbvie’s Humira® (adalimumab) Orphan Drug Designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (Hurley Stage II and Hurley Stage III disease), a painful, chronic inflammatory skin disease.
news
FDA grants Breakthrough Therapy Designation for venetoclax in 17p deletion relapsed-refractory chronic lymphocytic leukaemia
7 May 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation for venetoclax for the treatment of people who have relapsed or refractory CLL with 17p deletion...
news
AbbVie presents preliminary safety and efficacy data from its Phase 3b RUBY-I study
27 April 2015 | By Victoria White
AbbVie announced new, preliminary safety and efficacy data from the first cohort of its ongoing, Phase 3b RUBY-I study at ILC 2015...
news
EMA validates Marketing Authorisation Application for Zinbryta for treatment of MS
31 March 2015 | By Victoria White
Biogen and AbbVie have announced that the EMA has validated the companies’ MAA for Zinbryta for the treatment of relapsing forms of MS in the EU...
news
Thomson Reuters names most promising drugs of 2015
24 March 2015 | By Victoria White
The Intellectual Property and Science business of Thomson Reuters has released the 2015 edition of its annual Drugs to Watch report...
news
AbbVie acquires Pharmacyclics to help secure future cash flows as Humira biosimilars loom
6 March 2015 | By GlobalData
“AbbVie’s acquisition of Pharmacyclics (PCYC), valued at $21 billion, will help the company alleviate its dependency on Humira, which accounted for 62% of its total revenues in 2014, up from 57% in 2013..."
news
CHMP gives positive opinions of AbbVie’s VIEKIRAX™ and EXVIERA™
24 November 2014 | By Enanta Pharmaceuticals, Inc.
Enanta announces CHMP positive opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir(ABT-450)/ritonavir) + EXVIERA™ (dasabuvir) for the treatment of chronic hepatitis C in Europe...
